The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Pharma Impact Map
ABPI has published an interactive Pharma Impact Map, demonstrating the value of the pharmaceutical industry in different regional areas of all the four nations of the UK, down to constituency level. Data is available on economic value, manufacturing sites, jobs, NHS/industry collaborations, and research.
Partnering with purpose: How integrated care systems and industry can work better together
The NHS Confederation and the ABPI have published a joint report on how Integrated Care Systems (ICSs) and industry can work better together in the interests of patients.
NHS Industry Case Studies Library
Partnerships between the NHS and the pharmaceutical industry benefit patients and the NHS. Visit the ABPI's library of case studies of successful partnerships.
How to make sure patients get faster and fairer access to new medicines
In a new report, the ABPI's Patient Advisory Council says that UK governments and NHS leaders need to start with a holistic view of patient need and improve fair access to the latest medical advances.
ABPI launches new prescribing support guide for healthcare professionals
A new guide to how the pharmaceutical industry can help healthcare professionals with complex prescribing decisions has been launched today by the ABPI.
ABPI Exam name change to widen professional appeal
A key pharmaceutical qualification has been given a new name to reflect its broader relevance to roles across the industry.
The ABPI sets out its plan for investment, health and growth
The Association of the British Pharmaceutical Industry (ABPI) has published a manifesto outlining what a new government must do to make the UK the best place in the world to research, develop and use the medicines and vaccines of the future.
Latest blogs and events
June’s story of sickle cell
June has sickle cell, a genetic blood disorder that affects the red blood cells. She is one of the 1 in 17 people with a rare disease in the UK.
mRNA technology: navigating preclinical research for rare diseases
Philip Cruz, Country Medical Director at Moderna UK talks about the potential of mRNA technology for rare diseases in a blog for Rare Disease Day 2024.
Why we need the new Rare Therapies Launch Pad
The ABPI’s Director of Regulatory and Early Access Policy Dr Dan O’Connor looks forward to contributing to an innovative initiative to help improve patients’ access to personalised treatments for rare diseases.
Online Workshop on SMC: How to prepare and submit to SMC | 11-12 March 2024
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
Key content hubs
The COP28 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.